ES2605173T3 - Nanopéptidos derivados de calostro de mamífero para infecciones víricas y recurrentes de amplio espectro con un método de aislamiento de los mismos - Google Patents

Nanopéptidos derivados de calostro de mamífero para infecciones víricas y recurrentes de amplio espectro con un método de aislamiento de los mismos Download PDF

Info

Publication number
ES2605173T3
ES2605173T3 ES09827010.1T ES09827010T ES2605173T3 ES 2605173 T3 ES2605173 T3 ES 2605173T3 ES 09827010 T ES09827010 T ES 09827010T ES 2605173 T3 ES2605173 T3 ES 2605173T3
Authority
ES
Spain
Prior art keywords
nanopeptides
recurrent
infections
viral
broad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09827010.1T
Other languages
English (en)
Inventor
Pawan Saharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2605173T3 publication Critical patent/ES2605173T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

Una formulación que comprende una mezcla de péptidos aislados del calostro de mamíferos o péptidos sintéticos que tienen un peso molecular de menos de 10.000 Da, en donde la mezcla comprende cada uno de los péptidos que tienen secuencias tal como se expone en las SEQ ID NO. 1-8 que funcionan para modular la inmunidad celular y que proporcionan inhibición de unión para antígenos/virus exógenos sobre los receptores de la superficie celular.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
Figura 9: número de pacientes e intervalo de recuento de células CD4
imagen10
Carga vírica de VIH: después de 12 semanas de tratamiento con la serie 108 de RADHA, y al final del estudio la 5 carga vírica media mostró una reducción significativa (p < 0,001) respecto de la inicial.
Efectos secundarios: todos los pacientes toleraron bien la formulación de la presente invención sin efectos secundarios.
C. El resultado de los análisis estadísticos del estudio llevados a cabo en 50 pacientes VIH positivos es el siguiente: 10
Sr. No.
Parámetro Antes Después de 12 semanas Valor de P
I. Físicos (N=50)
1.
Peso 50,48 (10,97) 55,21 (9,42) <0,001
II. Síntomas clínicos (N=50)
1.
Fatiga 44 (88 %) 0 (0 %) <0,001
2.
Diarrea 9 (18,0 %) 0 (0 %) 0,004
3.
Náuseas 8 (16 %) 0 (0 %) 0,008
4.
Vómitos 7 (14 %) 0 (0 %) 0,02
5.
Fiebre 12 (24 %) 0 (0 %) <0,001
6.
Tos 14 (28 %) 0 (0 %) <0,001
7.
TB 6 (12 %) 0 (0 %) 0,03
8.
Alteraciones del sueño 13 (26 %) 0 (0 %) <0,001
9.
Erupción cutánea 7 (14 %) 0 (0 %) 0,02
10.
Herpes Zoster 6 (12 %) 0 (0 %) 0,03
III. Virológicos
1.
Log de ARN de VIHI, n=34 Mediana de ARN de VIHI Percentil 25º Percentil 75º 5,11 (0,090) 206057 62884 508038 4,103(1,32) 25280 1665 87511 <0,001 <0,001
IV. Inmunológicos
1.
Recuento de CD4 (N=48) Mediana Percentil 25º Percentil 75º 312,5 275,5 430 363,5 294,2 435 0,06
11

Claims (1)

  1. imagen1
ES09827010.1T 2008-12-27 2009-12-29 Nanopéptidos derivados de calostro de mamífero para infecciones víricas y recurrentes de amplio espectro con un método de aislamiento de los mismos Active ES2605173T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INMU13532008 2008-12-27
IN1353MU2008 2008-12-27
PCT/IN2009/000749 WO2010079511A2 (en) 2008-12-27 2009-12-29 Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof

Publications (1)

Publication Number Publication Date
ES2605173T3 true ES2605173T3 (es) 2017-03-13

Family

ID=42235438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09827010.1T Active ES2605173T3 (es) 2008-12-27 2009-12-29 Nanopéptidos derivados de calostro de mamífero para infecciones víricas y recurrentes de amplio espectro con un método de aislamiento de los mismos

Country Status (8)

Country Link
US (2) US8518454B2 (es)
EP (1) EP2370088B1 (es)
CA (1) CA2748449A1 (es)
DK (1) DK2370088T3 (es)
ES (1) ES2605173T3 (es)
SG (1) SG172793A1 (es)
WO (1) WO2010079511A2 (es)
ZA (1) ZA201104687B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5925391B2 (ja) * 2013-10-16 2016-05-25 日本水産株式会社 ペプチド又はその酸付加塩、飲食品、及び糖尿病予防等の組成物
US10842819B2 (en) * 2014-01-09 2020-11-24 Cmi Research Management, Llc Compositions and methods for treating itching, gingivostomatitis, and demodectic mange
WO2017192360A1 (en) * 2016-05-02 2017-11-09 Cmi Research Management, Llc Compositions and methods for treating itching caused by allergy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3468518B2 (ja) * 1991-12-23 2003-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニューロブラストーマ関連調節遺伝子
GB0001825D0 (en) * 2000-01-26 2000-03-22 Regen Therapeutics Plc Peptides
WO2001063293A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of schizophrenia
KR100423708B1 (ko) 2000-09-27 2004-03-24 주식회사 한국메디칼푸드 초유 분획을 유효성분으로 하는 면역증강제, 이의제조방법 및 용도
US20020127279A1 (en) 2001-03-12 2002-09-12 Matthews James S. Peptide-isolation process and product made thereby
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
KR20040106298A (ko) * 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
BRPI0507822A (pt) * 2004-03-01 2007-07-10 Peptera Pharmaceuticals Ltd método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna
US20070212367A1 (en) 2006-03-13 2007-09-13 Keech Andrew M Novel immunologically active peptide fragments of a proline-rich polypeptide isolated from colostral mammalian fluids for treatment of viral and non-viral diseases or diseased conditions

Also Published As

Publication number Publication date
EP2370088A2 (en) 2011-10-05
ZA201104687B (en) 2012-02-29
DK2370088T3 (en) 2017-02-20
WO2010079511A4 (en) 2011-03-10
US20130274177A1 (en) 2013-10-17
WO2010079511A2 (en) 2010-07-15
US9249188B2 (en) 2016-02-02
US20110319321A1 (en) 2011-12-29
WO2010079511A3 (en) 2010-11-25
US8518454B2 (en) 2013-08-27
CA2748449A1 (en) 2010-07-15
SG172793A1 (en) 2011-08-29
EP2370088B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
Beswick et al. Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection
Mina Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits
Scherle et al. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells.
ES2605173T3 (es) Nanopéptidos derivados de calostro de mamífero para infecciones víricas y recurrentes de amplio espectro con un método de aislamiento de los mismos
Meulemans et al. Protective effects of HN and F glycoprotein‐specific monoclonal antibodies on experimental newcastle disease
Wotring et al. Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern
Mohan et al. Antiviral activity of selected antimicrobial peptides against vaccinia virus
PE20110020A1 (es) Inmunomodulacion mediante el uso de celulas madres de la placenta
BR122019013216B8 (pt) ensaio imunológico para análise de uma vacina contra influenza
Vermeulen et al. Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus
CA2601006A1 (en) Cell strain capable of being cultured without ingredients derived from animals, method of producing the same, method of producing virus using the same, and method of producing vaccine
Zhang et al. Enhanced replication of virulent Newcastle disease virus in chicken macrophages is due to polarized activation of cells by inhibition of TLR7
Hornick et al. Kinetics and phenotype of the CD4 T cell response to influenza virus infections
WO2013102048A3 (en) Regenerative tissue matrix
Aouini et al. Viral interference between low pathogenic avian influenza H9N2 and avian infectious bronchitis viruses in vitro and in ovo
Wong et al. Changes in T cell homeostasis and vaccine responses in old age
Lupini et al. Alteration of immunological parameters in infectious bronchitis vaccinated–specific pathogen-free broilers after the use of different infectious bursal disease vaccines
Wang et al. Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice
Finney et al. Triphasic production of IFN γ by innate and adaptive lymphocytes following influenza A virus infection
ES2528951T3 (es) Secuencias consenso, antígenos y transgenes del VIH-1 del clado A
Planès et al. SARS-CoV-2 Envelope protein (E) binds and activates TLR2: A novel target for COVID-19 interventions
Jabri CD8α+ cDC1s integrate cell death signals to initiate inflammatory T cell immunity to dietary antigens following reovirus infection
Palomares et al. Acute infection with bovine viral diarrhea virus of low or high virulence leads to depletion and redistribution of WC1+ γδ T cells in lymphoid tissues of beef calves
Payne et al. ‘It's just a virus’–viral illness in older people: prevention and management
Esposito et al. Tracking the 2009 H1N1 influenza virus in the Italian region Campania